GlassScriptPhysician profile
Karen D Walker
NPI 1669430872
$7,975.72
in general payments reported to CMS, 2019-2025
33 companies · $1,117 in 2025
The $1,117 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,141 · 2020: $816 · 2021: $1,261 · 2022: $856 · 2023: $995 · 2024: $1,790 · 2025: $1,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,901.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,145.81 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $1,249.80 | 2019-2025 | |
| Janssen Biotech, INC. | $540.23 | 2019-2025 | Tremfya |
| Leo Pharma INC. | $539.92 | 2019-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $363.94 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $363.21 | 2019-2025 | Aklief, Oracea, Epsolay |
| Regeneron Healthcare Solutions, INC. | $354.63 | 2019-2025 | Dupixent, Libtayo |
| Revance Therapeutics, INC. | $270.98 | 2024 | Daxxify |
| Sun Pharmaceutical Industries INC. | $269.14 | 2019-2024 | Ilumya |
| Genzyme Corporation | $264.74 | 2019-2025 | |
| Amgen INC. | $247.21 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $226.57 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $196.70 | 2019-2025 | Duobrii, Targretin, Siliq |
| Arcutis Biotherapeutics, INC. | $193.69 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $171.51 | 2019-2025 | Taltz, Ebglyss |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $141.83 | 2019-2025 | |
| Celgene Corporation | $90.85 | 2019 | |
| Aclaris Therapeutics, INC. | $48.63 | 2019 | |
| Almirall LLC | $38.06 | 2019 | |
| Dermavant Sciences, INC. | $37.05 | 2023 | Vtama |
| Dusa Pharmaceuticals, INC. | $23.76 | 2019 | |
| Ucb, INC. | $21.38 | 2021 | |
| Verrica Pharmaceuticals INC. | $18.98 | 2024 | Ycanth |
| Botanix Sb INC | $18.30 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.41 | 2023 | Spevigo |
| Incyte Corporation | $16.78 | 2024 | Opzelura |
| Fresenius Kabi USA, LLC | $15.91 | 2023 | Idacio |
| Taro Pharmaceuticals USA, INC. | $15.79 | 2019 | |
| Allergan, INC. | $15.64 | 2019 | |
| Organon LLC | $15.48 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $14.67 | 2020 | |
| Convatec INC. | $14.27 | 2025 | |
| Mission Pharmacal Company | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.